Lundbeck maintains guidance after exceeding expectations in Q1

After surpassing the consensus analyst estimate in terms of operating result and revenue, Lundbeck is maintaining its guidance for the full-year 2022.

Photo: Jens Dresling

Lundbeck has released its report for the first three months of 2022, which reveals revenue and EBIT (earnings before interest and taxes) results that exceed the analyst consensus estimates.

Analysts had predicted an EBIT result of DKK 731m (USD 103.7m), which Lundbeck exceeded with a result of DKK 875m (USD 124m). Revenue was predicted to land at DKK 4.2bn (USD 600m) by analysts, but totaled DKK 4.4bn (USD 620m) for the period.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Further reading

Related articles

Latest news

See all jobs